1. 三欧吉Home
  2. 辟谣啦

疑/尚无定论 - 有抗体的新冠肺炎治愈者不会再感染,可以发免疫护照

流传说法:

较真鉴定: 尚无定论
查证要点:
  • 现阶段尚无足够证据证明抗体介导免疫的有效性,不能保证新型冠状肺炎治愈者不会再次感染,因此也无法保证“免疫护照”的准确性。
  • 通过自然感染对病毒产生免疫需要经过多个步骤,人体从而产生联合适应性免疫应答清除毒素,如果应答足够强就可防止同一病毒再次感染。这通过血液中抗体的存在来衡量。
  • 目前大多数研究表明,康复的感染者拥有对该病毒的抗体。但截至2020年4月24日,尚无研究评估SARS-CoV-2抗体能否使人类免疫后续感染。
  • 对人体内SARS-CoV-2抗体的实验室检测,其准确性和可靠性仍需要进一步验证。免疫诊断检测如果不准确,可能会导致:第一,将已感染者标记为阴性,第二,将未感染者标记为阳性。
查证者:世界卫生组织联合国系统内卫生问题的指导和协调机构

参考文献
  • ConsiderationsinadjustingpublichealthandsocialmeasuresinthecontextofCOVID-19.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/critical-preparedness-readiness-andresponse-actions-for-covid-19
  • WölfelR,CormanVM,GuggemosW,etal.VirologicalassessmentofhospitalizedpatientswithCOVID-2019.Nature2020.
  • ToKK,TsangOT,LeungWS,etal.TemporalprofilesofviralloadinposteriororopharyngealsalivasamplesandserumantibodyresponsesduringinfectionbySARS-CoV-2:anobservationalcohortstudy.LancetInfectDis.2020Mar23.pii:S1473-3099(20)30196-1.doi:10.1016/S1473-3099(20)30196-1.
  • WuF,WangA,LiuM,etal.NeutralizingantibodyresponsestoSARS-CoV-2inaCOVID-19recoveredpatientcohortandtheirimplications.medRxiv2020:2020.03.30.20047365.
  • JuB,ZhangQ,GeX,etal.PotenthumanneutralizingantibodieselicitedbySARS-CoV-2infection.Biorxiv2020:2020.03.21.990770.
  • PohCM,CarissimoG,WangB,etal.PotentneutralizingantibodiesintheseraofconvalescentCOVID-19patientsaredirectedagainstconservedlinearepitopesontheSARS-CoV-2spikeprotein.Biorxiv2020:2020.03.30.015461.
  • ZhangW,DuR,LiB,ZhengX,etal.Molecularandserologicalinvestigationof2019-nCoVinfectedpatients:implicationofmultiplesheddingroutes.EmergMicrobesInfect.2020Feb17;9(1):386-389.doi:10.1080/22221751.2020.1729071.
  • GrzelakL,TemmamL,PlanchaisC,etal.SARS-CoV-2serologicalanalysisofCOVID-19hospitalizedpatients,paucisymptomaticindividualsandblooddonors.medRxiv2020(submitted17April2020).
  • AmanatF,NguyenT,ChromikovaV,etal.AserologicalassaytodetectSARS-CoV-2seroconversioninhumans.medRxiv2020:2020.03.17.20037713.
  • OkbaNMA,MüllerMA,LiW,etal.Severeacuterespiratorysyndromecoronavirus2−specificantibodyresponsesincoronavirusdisease2019patients.EmergInfectDis.2020doi:10.3201/eid2607.200841
  • ZhaoJ,YuanQ,WangH,etal.AntibodyresponsestoSARS-CoV-2inpatientsofnovelcoronavirusdisease2019.ClinInfectDis.2020doi:10.1093/cid/ciaa344
  • GuoL,RenL,YangS,etal.ProfilingEarlyHumoralResponsetoDiagnoseNovelCoronavirusDisease(COVID-19).ClinInfectDis.2020Mar21.doi:10.1093/cid/ciaa310.
  • LiuY,LiuY,DiaoB,RenFeifei,etal.DiagnosticindexesofarapidIgG/IgMcombinedantibodytestforSARS-CoV-2.medRxiv2020;doi:10.1101/2020.03.26.20044883
  • ZhangP,GaoQ,WangT,KeY,etal.Evaluationofrecombinantnucleocapsidandspieproteinserologicaldiagnosisofnovelcoronavirusdisease2019(COVID-19).medRxiv.2020;doi:10.1101/2020.03.17.20036954
  • PanY,LiX,YangG,FanJ,etal.SerologicalimmunochromatographicapproachindiagnosiswithSARS-CoV-2infectedCOVID-19patients.medRxiv.2020;doi:10.1101/2020.03.13.20035428
  • LiZ,YiY,LuoX,XionN,etal.DevelopmentandclinicalapplicationofarapidIgM-IgGcombinedantibodytestforSARSCoV-2infectiondiagnosis.JMedVirol.2020Feb27.doi:10.1002/jmv.25727.
  • LiR,PeiS,ChenB,etal.Substantialundocumentedinfectionfacilitatestherapiddisseminationofnovelcoronavirus(SARSCoV2).Science2020.
  • LouB,LiT,ZhengS,SuY,LiZ,LiuW,etal.SerologycharacteristicsofSARS-CoV-2infectionsincetheexposureandpostsymptomsonset.medRxiv2020;doi:10.1101/2020.03.23.20041707
  • LinD,LiuL,ZhangM,HuY,etal.Evaluationofserologicaltestsinthediagnosisof2019novelcoronavirus(SARS-CoV-2)infectionsduringtheCOVID-19outbreak.medRxiv2020.doi:10.1101/2020.03.27.20045153
  • LiuW,LiuL,KouG,ZhengY,etal.Evaluationofnucleocapsidandspikeprotein-basedELISAsfordetectingantibodiesagainstSARS-CoV-2.medxriv[Internet].2020;Availablefrom:https://doi.org/10.1101/2020.03.16.20035014medRxivpreprint
  • UnityStudies:EarlyInvestigationProtocolshttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/early-investigations
展开


推荐大师影视搜索
点这里有美女看哦~

原创文章,作者:三欧吉,如若转载,请注明出处:https://www.3og.cn/19801.html

Contact Us

400-800-8888

在线咨询:点击这里给我发消息

邮件:uxgecn@qq.com

工作时间:周一至周五